ArticleBMC anesthesiology2025
Comparison of remimazolam tosylate and propofol in hemodynamic stability, postoperative cognitive function, and recovery in general anesthesia combined with regional nerve blocks: a retrospective cohort study.
Article in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Blood Pressure Reduction During Anesthetic Induction with Remimazolam versus Propofol in Elderly Patients: Pharmacodynamic Modeling of Remimazolam.Drug design, development and therapy · 2025Trial
- The Effects of Low-Dose Remimazolam Adjunct on Propofol-Remifentanil Anaesthesia in Day Case Gynaecological Surgery: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Age‑stratified median effective dose (ED₅₀) of remimazolam besylate for successful gastroscope insertion without body movement in geriatric patients.BMC anesthesiology · 2026Article
- Comparison of Remimazolam and Propofol in Large Skull Base Tumor Resections: Effects on Hemodynamic Stability, Neurocognitive Recovery, and Inflammatory Response.Drug design, development and therapy · 2026Article
- Comparison of intraoperative hemodynamic parameters between propofol- and remimazolam-based total intravenous anesthesia in patients undergoing robotic gynecologic surgery: a randomized controlled trial protocol.Frontiers in pharmacology · 2026Article
- Hypotension incidence comparison between remimazolam and propofol in hypertensive patients undergoing spinal surgery.American journal of translational research · 2026Article
- Short- and long-term effects of single neonatal exposure to propofol anesthesia on cognitive function.The Journal of international medical research · 2025Article
- Comparative Effects of Remimazolam and Propofol on Intraoperative Hypertension and Hypotension During Robot-Assisted Laparoscopic Gynecologic Surgery: A Retrospective Analysis.Medicina (Kaunas, Lithuania) · 2025Article
- Current and Emerging Sedation Practices for Colonoscopy: A Narrative Review of Pharmacological Agents, High-Risk Populations, and Safety Considerations.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGeneral anesthesia (GA) combined with regional anesthesia (RA) is commonly used to enhance perioperative analgesia and hemodynamic stability. This study aimed to compare the hemodynamic effects and postoperative cognitive function between remimazolam tosylate and propofol in patients undergoing GA combined with RA.
methodsA retrospective cohort study was conducted on 4408 patients who underwent elective upper or lower limb surgeries at our institution from January 2020 to June 2024. Patients were divided into two groups: Remimazolam (n = 2391) and Propofol (n = 2017). The primary outcomes included hemodynamic parameters (systolic blood pressure [SBP], diastolic blood pressure [DBP], heart rate [HR], mean arterial pressure [MAP]) and postoperative cognitive function (Montreal Cognitive Assessment [MoCA] scores at 24, 48, and 72 h). Secondary outcomes included anesthetic drug consumption, adverse events, and recovery times.
resultsThe Remimazolam group was associated with more stable hemodynamic parameters, with significantly higher SBP (121.4 ± 8.3 vs. 112.6 ± 9.2 mmHg, p < 0.05), DBP (72.3 ± 6.1 vs. 67.8 ± 5.9 mmHg, p < 0.05), and MAP (88.3 ± 7.4 vs. 83.1 ± 7.2 mmHg, p < 0.05) compared to the Propofol group. Postoperative cognitive function was superior in the Remimazolam group, with higher MoCA scores at 24, 48, and 72 h (19.6 ± 2.1 vs. 16.3 ± 3.4 at 24 h, p < 0.05). The Remimazolam group also had lower anesthetic consumption (0.16 ± 0.02 vs. 2.4 ± 0.3 mg/kg, p < 0.05), faster recovery times (extubation 8.4 ± 2.1 vs. 11.2 ± 3.4 min, p < 0.05), and fewer adverse events (hypotension: 14% vs. 28%, p < 0.05).
conclusionRemimazolam tosylate was associated with more stable hemodynamic parameters, lower rates of postoperative cognitive dysfunction, and shorter recovery times compared to propofol in patients undergoing GA combined with RA, suggesting it may be a safer alternative for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.